Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ULESFIA is a topical lotion formulation of benzyl alcohol approved for the treatment of head lice infestations. It is a pediculicide that works through a physical mechanism rather than neurotoxic action, making it suitable for use across diverse patient populations including those with pyrethroid resistance.
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting defensibility challenges and a focus on operational efficiency and portfolio transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ULESFIA offers 44 linked career opportunities with emphasis on commercial execution, market access, and regulatory compliance as the product approaches loss of exclusivity. Roles span sales leadership, value/access strategy, and quality operations, reflecting the focus on operational excellence and market defense in a mature product's later lifecycle stage.
Worked on ULESFIA at Shionogi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
44 open roles linked to this drug